Across TCGA pan-cancer cohorts, TRAV12-2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRAV12-2 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRAV12-2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAV12-2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

HNSC, BLCA, and LUSC are the cancer types where TRAV12-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.187	0.710	.014	12	view →
BLCA	DFS	Median	III,IV	0.083	0.572	<.001	12	view →
LUSC	DFS	Median	All	0.185	0.748	.010	9	view →
UCEC	DFS	Median	All	1.000	0.629	.031	8	view →
SKCM	DFS	Median	All	1.000	0.622	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TRAV12-2 tumor-vs-normal RNA expression · all TRAV12-2 data types